Ovarian cancer, because of its low cure rate, is responsible for 5% of all cancer deaths in women. It is estimated that ovarian cancer caused 12,180 deaths in the United States in 2006. The majority of ovarian cancer cases are detected at an advanced stage (with metastases present beyond the ovaries), when disease is rarely curable. However, although most patients with advanced disease die within 2 years of diagnosis, a subset of these patients develop a more chronic form of ovarian cancer and survive 5 years or more with treatment. It is possible that patients with indolent cancer should be monitored and treated differently from patients with rapidly progressing ovarian cancer. However, at this point, clinicians do not have the tools to predict the clinical course of disease. Using a newly developed expression tag oligonucleotide array comparative genomic hybridization (CGH) platform, we have recently identified 12 CGH segments associated with overall survival in patients with high-grade, advanced-stage serous adenocarcinoma of the ovary. We found that DNA copy numbers of 91 genes in the 12 CGH segments were significantly correlated with transcription levels of those genes as evaluated by transcriptional profiling of RNA isolated from the same set of microdissected tumor tissue samples. In an independent set of high-grade, advanced-stage serous adenocarcinoma specimens, validation studies on one of these genes-FGF1, located on 5q31-showed that mRNA copy number was significantly correlated with DNA copy number and protein expression levels and that both FGF1 mRNA and FGF1 protein levels were significantly associated with worse overall patient survival. These data suggest that the combination of array CGH and expression profiling can successfully identify genetic biomarkers with prognostic value. Our long-term goal is to develop a genetic prognostic model for high- grade, advanced-stage serous adenocarcinoma. We have 3 specific aims: (1) Verify the correlation between DNA copy number abnormalities and gene expression for genes located in the 12 CGH segments that are significantly associated with overall and progression free survival in patients with high-grade, advanced stage serous adenocarcinoma. (2) Perform further validation studies utilizing an independent set of samples obtained from patients entered on Gynecologic Oncology Group protocol 218 and develop a provisional genetic prognostic model for high-grade, advanced stage serous adenocarcinoma. (3) Validate the prognostic value of each candidate marker using genetically characterized ovarian cancer cell lines and orthotopic mouse models. We believe that our combination of array CGH and expression profiling will allow us to identify functionally significant markers that are associated with reduced survival duration. These markers could be used to detect aggressive cancers and stratify patients into prognostic groups;could serve as therapeutic targets;and could facilitate patient stratification for phase III clinical trials.
The proposed studies seek to perform further validation studies on genes located in the 12 comparative genomic hybridization (CGH) segments that are significantly associated with progression free and overall survival in patients with high-grade advanced stage serous ovarian cancer using a large collection of clinical trial specimens. Validated genetic changes will be used to compare with those identified in other histological types of ovarian cancers. By combining with transcriptional profiling data, validated candidate genes will be used to develop a genetic prognostic model for the disease. We will focus on genes that are associated with worse overall and progression free survival and with chemoresistance for further functional studies. A panel of genetically characterized ovarian cancer cell lines and an orthotopic ovarian cancer mouse model will be used to further validate the prognostic value of each selected candidate marker.
|Yeung, Tsz-Lun; Leung, Cecilia S; Li, Fuhai et al. (2016) Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. Biomolecules 6:3|
|Au Yeung, Chi Lam; Co, Ngai-Na; Tsuruga, Tetsushi et al. (2016) Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 7:11150|
|Mullany, Lisa K; Wong, Kwong-Kwok; Marciano, David C et al. (2015) Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival. Neoplasia 17:789-803|
|Moran-Jones, Kim; Gloss, Brian S; Murali, Rajmohan et al. (2015) Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget 6:44551-62|
|Yeung, Tsz-Lun; Leung, Cecilia S; Yip, Kay-Pong et al. (2015) Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. Am J Physiol Cell Physiol 309:C444-56|
|Leung, Cecilia S; Yeung, Tsz-Lun; Yip, Kay-Pong et al. (2014) Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun 5:5092|
|Song, Huijuan; Kwan, Suet-Yan; Izaguirre, Daisy I et al. (2013) PAX2 Expression in Ovarian Cancer. Int J Mol Sci 14:6090-105|
|Wong, Kwong-Kwok; Izaguirre, Daisy I; Kwan, Suet-Yan et al. (2013) Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol 130:565-9|
|Zaid, Tarrik M; Yeung, Tsz-Lun; Thompson, Melissa S et al. (2013) Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res 19:809-20|
|Yeung, Tsz-Lun; Leung, Cecilia S; Wong, Kwong-Kwok et al. (2013) TGF-Î² modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res 73:5016-28|
Showing the most recent 10 out of 20 publications